NeuroPace, Inc. provided updates on its financial guidance for 2025, reaffirmed preliminary financial results for 2024, and shared clinical trial data showing significant seizure reduction in patients with focal epilepsy, with 62.5% median seizure reduction at 6 months and 82.0% at 36 months post-implant.